The Expression of P63 Marker in Malignant and Benign Breast Tumors

This is a retrospective study conducted on Sudanese patients from January 2021 to May 2021 at the radiation and isotope center in Khartoum. In this study we aimed to determine the expression of P63 marker in malignant and benign breast tumors. One hundred paraffin-embedded blocks previously diagnosed as breast tumors were collected. The study included 65 (65%) samples of malignant and 35 (35%) benign samples. All these samples were Immunohistochemically stained by using monoclonal antibodies (by indirect streptavidin-biotin technique) for p63. All immune-stained slides were scored as either positive or negative. Data collected from patient file and results were analyzed using social science statistic web SPSS computer program.